Central Nervous System Tumour, Arteriovenous Malformation
Conditions
Brief summary
Open label, multi-centre prospective study. Adult patients with primary central nervous system tumours fulfilling the inclusion criteria according to the study protocol. The study consists of 2 sequential cohorts evaluated consecutively for the feasibility, safety and toxicity, as well as long-term survival data, when using spot scanning proton beam therapy.
Detailed description
Open label, multi-centre prospective phase II study. Adult patients with primary central nervous system tumours full-filling the inclusion criteria according to the study protocol. The study consists of 2 sequential cohorts evaluated for the feasibility, safety and toxicity, as well as long-term survival data, when using proton beam therapy. * Part I: To assess the feasibility of using pencil beam scanning and evaluating the treatment safety in all aspects, and to assess acute toxicity in a smaller cohort of CNS patients. All toxicity data, QoL and survival data will also be included in the part II cohort. * Part II: The second part of the trial consists of all CNS patients that are referred to the Skandion Clinic after the safety data from the first part has been evaluated by the study steering committee.
Interventions
RADIATIONProton radiotherapy
Sponsors
Sahlgrenska University Hospital
Karolinska University Hospital
University Hospital, Umeå
Region Örebro County
University Hospital, Linkoeping
Uppsala University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The patient must be at least 18 years old * World Health Organization (WHO)/ Eastern Cooperative OncologyGroup (ECOG) performance status 0-2, Karnofsky score ≥60. * The patient must be able to understand the information about the treatment and give a written informed consent to participate in the trial. * Adequate follow-up study must be possible; this will exclude a patient who is uncooperative. * Must have a life expectancy of at least 3 years based on age and co-morbidities as well as diagnosis. For patients considered for re-irradiation the life expectancy must be estimated to minimum 6 months. * Must have a pathology proven CNS tumour or if not possible, the radiology findings must be evaluated at a multi-disciplinary conference at a university hospital. * Women of reproductive potential must agree to use an effective method of contraception during therapy such as an intrauterine device or condom. Pregnancy IS not an ineligibility criteria if radiotherapy is indicated and can-not be postponed. * Prior CNS radiotherapy is not an ineligibility criteria but re-irradiated patients will be included in a subgroup evaluated separately. Patients discussed at multidisciplinary conferences at one of the seven university hospitals in Sweden and found candidates for radiotherapy and one of following diagnoses: * Anaplastic glioma grade III with Loss of Heterozygosity (LOH) 1p/19q and isocitrate dehydrogenase-1 (IDH-1) mutation * Arteriovenous malformations (AVMs) * Chordomas and chondrosarcomas * Craniopharyngiomas * Ependymomas * Intracranial germ cell tumours * Low grade gliomas - grade I-II * Medulloblastoma, Primitive neuroectodermal tumour (PNET) * Meningiomas * Neurocytoma * Other grade I-II primary CNS tumour according to WHO classification * Pituitary adenomas * Schwannomas * Spinal tumours * Whenever craniospinal irradiation (CSI) is indicated * Whenever re-irradiation of CNS is considered
Exclusion criteria
* Concomitant or previous malignancies. Exceptions are adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, or in situ carcinoma of the cervix uteri with a follow-up time of at least 3 years, or other previous malignancy with a disease-free interval of at least 5 years. * Not able to understand information or manage tests according to study protocol. If necessary, only authorized interpreters may be used to assist in the translation. * Psychiatric or addictive disorders or other medical conditions that, in the opinions of the investigator, would preclude the patient from meeting the study requirements.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Acute adverse events | 3 months | — |
| Long-term adverse events | 10-15 years | This study specifically includes longitudinal follow-up to assess the incidence of neurotoxicity including cognitive dysfunction, as well as the incidence of secondary malignant neoplasms at 10 and 15 years following radiotherapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Local and regional tumour control | 15 years | Including overall survival |
| Pattern of failure | 15 years | Pattern of failure on MRI will be compared with patients getting conventional radiotherapy. |
| Quality of life | 5 years | Quality of Life (QoL) data will be evaluated using validated questionnaires from the European Organization for Research and Treatment of Cancer (EORTC): EORTC-QLQ-C30 is a multidimensional, cancer-specific QoL questionnaire developed for repeated assessments in clinical trials, and validated in various cancer populations. The Brain Cancer Module (EORTC-QLQ-BN20) includes 20 questions focusing on neurological symptoms and EuroQoL (EQ-5D) may additional also be used in the study. |
| Normal tissue sparing and normal tissue complication | 15 years | Normal tissue complication probability (NTCP) models will be used to evaluate the reduction in normal tissue complications in dose planning studies comparing proton radiotherapy vs. 3D-Conformal Radiotherapy (CRT), Intensity Modulated Radiotherapy (IMRT)/Volumetric Modulated Arc Therapy (VMAT)/Helical Tomotherapy (HTT). |
Countries
Sweden
Contacts
Primary ContactPetra Witt Nystrom, MD, PhD
Outcome results
None listed